A Phase II Evaluation of AMG 102 (Rilotumumab) In The Treatment Of Persistent Or Recurrent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma: A Gynecologic Oncology Group Study

PURPOSE: This open-label, multi-institutional Phase II trial evaluated activity and safety of rilotumumab (AMG 102), a monoclonal antibody that targets HGF (hepatocyte growth factor), the ligand for the MET receptor, in women with recurrent or persistent epithelial ovarian, fallopian tube or primary...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gynecol Oncol
Autors principals: Martin, Lainie P., Sill, Michael, Shahin, Mark S., Powell, Matthew, DiSilvestro, Paul, Landrum, Lisa M., Gaillard, Stephanie L., Goodheart, Michael J., Hoffman, James, Schilder, Russell J.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4469031/
https://ncbi.nlm.nih.gov/pubmed/24361733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.12.018
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars